Valneva SE American Depositary Shares (VALN) is a publicly traded Healthcare sector company. As of May 21, 2026, VALN trades at $5.83 with a market cap of $541.44M and a P/E ratio of 0.00. VALN moved +2.34% today. Year to date, VALN is -33.11%; over the trailing twelve months it is -6.62%. Its 52-week range spans $3.62 to $12.25. Analyst consensus is buy with an average price target of $12.23. Rallies surfaces VALN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Valneva Q1 Revenue Drops, Loss Widens; Focus on Cash as Lyme Vaccine Review Nears: Valneva’s first-quarter 2026 revenue fell year over year and its net loss widened as it conserves cash ahead of regulatory review of its Lyme disease vaccine candidate with Pfizer. The company said cost control remains a priority while awaiting a U.S. advisory committee meeting later this year.
| Metric | Value |
|---|---|
| Price | $5.83 |
| Market Cap | $541.44M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.25 |
| 52-Week Low | $3.62 |
| Volume | 13 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
4 analysts cover VALN: 0 strong buy, 3 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $12.23.